Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

TransMedics Group, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

ANDOVER, MASS. , AUG. 4, 2025 /PRNEWSWIRE/ -- TRANSMEDICS GROUP, INC. ("TRANSMEDICS") (NASDAQ: TMDX), A MEDICAL TECHNOLOGY COMPANY THAT IS TRANSFORMING ORGAN TRANSPLANT THERAPY FOR PATIENTS WITH END-STAGE LUNG, HEART, AND LIVER FAILURE, TODAY ANNOUNCED THAT THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS GRANTED CONDITIONAL APPROVAL OF ITS INVESTIGATIONAL DEVICE EXEMPTION (IDE), ALLOWING THE COMPANY TO PROCEED WITH THE INITIATION OF ITS NEXT-GENERATION OCS ENHANCE HEART TRIAL.

TRANSMEDICS RECEIVES FDA IDE APPROVAL TO INITIATE NEXT-GENERATION OCS HEART TRIAL

ANDOVER, MASS. , AUG. 1, 2025 /PRNEWSWIRE/ -- TRANSMEDICS GROUP, INC. ("TRANSMEDICS") (NASDAQ: TMDX), A MEDICAL TECHNOLOGY COMPANY THAT IS TRANSFORMING ORGAN TRANSPLANT THERAPY FOR PATIENTS WITH END-STAGE LUNG, HEART, AND LIVER FAILURE,TODAY ANNOUNCED THAT ON JULY 28, 2025, TRANSMEDICS GRANTED NON-QUALIFIED STOCK OPTIONS TO PURCHASE AN AGGREGATE OF 21,458 SHARES OF ITS COMMON STOCK AND AN AGGREGATE OF 14,283 RESTRICTED STOCK UNITS TO 14 EMPLOYEES, EACH AS A MATERIAL INDUCEMENT FOR EACH EMPLOYEE'S ENTRY INTO EMPLOYMENT WITH TRANSMEDICS.

TRANSMEDICS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

ANDOVER, MASS. , JULY 30, 2025 /PRNEWSWIRE/ -- TRANSMEDICS GROUP, INC. ("TRANSMEDICS") (NASDAQ: TMDX), A MEDICAL TECHNOLOGY COMPANY THAT IS TRANSFORMING ORGAN TRANSPLANT THERAPY FOR PATIENTS WITH END-STAGE LUNG, HEART, AND LIVER FAILURE, TODAY REPORTED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2025.

TRANSMEDICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS

ANDOVER, MASS. , JULY 29, 2025 /PRNEWSWIRE/ -- TRANSMEDICS GROUP, INC. ("TRANSMEDICS") (NASDAQ: TMDX), A MEDICAL TECHNOLOGY COMPANY THAT IS TRANSFORMING ORGAN TRANSPLANT THERAPY FOR PATIENTS WITH END-STAGE LUNG, HEART, AND LIVER FAILURE, TODAY ANNOUNCED THAT MEMBERS OF THE MANAGEMENT TEAM WILL PRESENT AT THE UPCOMING CANACCORD GENUITY 45TH ANNUAL GROWTH CONFERENCE AT THE INTERCONTINENTAL BOSTON HOTEL.

TRANSMEDICS TO PRESENT AT THE CANACCORD GENUITY 45TH ANNUAL GROWTH CONFERENCE

ANDOVER, MASS. , JULY 16, 2025 /PRNEWSWIRE/ -- TRANSMEDICS GROUP, INC. ("TRANSMEDICS") (NASDAQ: TMDX), A MEDICAL TECHNOLOGY COMPANY THAT IS TRANSFORMING ORGAN TRANSPLANT THERAPY FOR PATIENTS WITH END-STAGE LUNG, HEART AND LIVER FAILURE, TODAY ANNOUNCED THAT IT WILL RELEASE FINANCIAL RESULTS FOR THE SECOND QUARTER 2025 AFTER MARKET CLOSE ON WEDNESDAY, JULY 30, 2025.

TRANSMEDICS TO REPORT SECOND QUARTER 2025 FINANCIAL RESULTS ON JULY 30, 2025

NEW YORK, JUNE 10, 2025 (GLOBE NEWSWIRE) -- KUEHN LAW, PLLC, A SHAREHOLDER LITIGATION LAW FIRM, IS INVESTIGATING WHETHER CERTAIN OFFICERS AND DIRECTORS OF TRANSMEDICS GROUP, INC. (NASDAQ: TMDX) BREACHED THEIR FIDUCIARY DUTIES TO SHAREHOLDERS.

KUEHN LAW ENCOURAGES INVESTORS OF TRANSMEDICS GROUP, INC. TO CONTACT LAW FIRM

NEW YORK , MAY 27, 2025 /PRNEWSWIRE/ --KUEHN LAW, PLLC, A SHAREHOLDER LITIGATION LAW FIRM, IS INVESTIGATING WHETHER CERTAIN OFFICERS AND DIRECTORS OF TRANSMEDICS GROUP, INC. (NASDAQ: TMDX) BREACHED THEIR FIDUCIARY DUTIES TO SHAREHOLDERS. ACCORDING TO A FEDERAL SECURITIES LAWSUIT, INSIDERS AT TRANSMEDICS CAUSED THE COMPANY TO MISREPRESENT OR FAIL TO DISCLOSE (1) TRANSMEDICS USED KICKBACKS, FRAUDULENT OVERBILLING, AND COERCIVE TACTICS TO GENERATE BUSINESS AND REVENUE; (2) TRANSMEDICS ENGAGED IN UNSAFE PRACTICES AND HID SAFETY ISSUES AND GENERALLY LACKED SAFETY OVERSIGHT; (3) THE FOREGOING SUBJECTED TRANSMEDICS TO HEIGHTENED RISK OF SCRUTINY AND REGULATORY RISK; AND (4) AS A RESULT, STATEMENTS ABOUT TRANSMEDICS' BUSINESS, OPERATIONS, AND PROSPECTS, WERE MATERIALLY FALSE AND MISLEADING AND/OR LACKED A REASONABLE BASIS AT ALL RELEVANT TIMES.

ANDOVER, MASS. , MAY 27, 2025 /PRNEWSWIRE/ --TRANSMEDICS GROUP, INC. ("TRANSMEDICS") (NASDAQ: TMDX), A MEDICAL TECHNOLOGY COMPANY THAT IS TRANSFORMING ORGAN TRANSPLANT THERAPY FOR PATIENTS WITH END-STAGE LUNG, HEART, AND LIVER FAILURE,TODAY ANNOUNCED THAT ON MAY 21, 2025, TRANSMEDICS GRANTED NON-QUALIFIED STOCK OPTIONS TO PURCHASE AN AGGREGATE OF 9,940 SHARES OF ITS COMMON STOCK AND AN AGGREGATE OF 6,670 RESTRICTED STOCK UNITS TO 15 EMPLOYEES, EACH AS A MATERIAL INDUCEMENT FOR EACH EMPLOYEE'S ENTRY INTO EMPLOYMENT WITH TRANSMEDICS.

ANDOVER, MASS. , MAY 20, 2025 /PRNEWSWIRE/ -- TRANSMEDICS GROUP, INC. ("TRANSMEDICS") (NASDAQ: TMDX), A MEDICAL TECHNOLOGY COMPANY THAT IS TRANSFORMING ORGAN TRANSPLANT THERAPY FOR PATIENTS WITH END-STAGE LUNG, HEART, AND LIVER FAILURE, TODAY ANNOUNCED THE COMPANY WILL BE PARTICIPATING IN TWO UPCOMING INVESTOR CONFERENCES.

TRANSMEDICS TO PRESENT AT UPCOMING JUNE INVESTOR CONFERENCES

ANDOVER, MASS. , MAY 8, 2025 /PRNEWSWIRE/ -- TRANSMEDICS GROUP, INC. ("TRANSMEDICS") (NASDAQ: TMDX), A MEDICAL TECHNOLOGY COMPANY THAT IS TRANSFORMING ORGAN TRANSPLANT THERAPY FOR PATIENTS WITH END-STAGE LUNG, HEART, AND LIVER FAILURE, TODAY REPORTED FINANCIAL RESULTS FOR THE QUARTER ENDED MARCH 31, 2025.

TransMedics Group, Inc.

TMDX

Price

Financials Overview

Financial Reports

No items found.

Press Releases

TransMedics Group, Inc.

TMDX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

TMDX